Although the PARP1 inhibitor olaparib emerges as a promising tool to modulate PARP1/BRG1/EP300-dependent gene expression due to its safety and well-established in vivo effects in cancer treatment, the functional impact of DNA repair gene repression in anticancer therapies requires further investigation. This evidence concerns the gene SMARCA4 and cancer.